Market Overview

Viscosupplementation Market size was valued at USD 7.9 Billion in 2023 and is projected to reach USD 17.50 Billion by 2032, growing at a CAGR of 9.24% from 2024 to 2032.

Viscosupplementation is used mainly in the treatment for osteoarthritis and consists of an injection of medication in the form of gel into the joint. The therapeutic outcome is the reduction of pain, an improved joint function, and quality of life in patients with this degenerative disease. Viscosupplementation generally involves the use of a gel, most commonly hyaluronic acid, which acts as a natural body chemical that is present in the joint fluid normally and serves as a lubricant to reduce friction. In effect, during the course of osteoarthritis, there is a reduction of hyaluronic acid in the joint fluid. Therefore, viscosupplementation helps to return the normal fluidity of synovial fluid and, subsequently, reduce the friction and RAISE mobility.

The 1980s marked the beginning of viscosupplementation when the first studies were conducted to investigate the effectiveness of HA injections in the treatment of joint diseases. The application has continually been accepted over the years, and it is now considered as a routine and conventional treatment method for the management of knee osteoarthritis. Extensive research has enlarged the application of the application of the above treatment form to the hip, shoulder, and ankle joints. Treatment for most products is conducted in a series of injections, but the number and time frame for the injections/printing vary with each product and are dependent on severity of the condition being treated.

Results vary from patient to patient, but many patients have been found to benefit with tremendous relief from pain as well as increased joint mobility subsequent to viscosupplementation. Clinical trials have proven that these benefits are long-lasting, from 6 to more than 12 months, based on patient-specific factors and the type of hyaluronic acid. Moreover, the procedure is minimally invasive and hence carries fewer risks than the more invasive or non-surgical options available, so it is highly favored for most of the patients who are still not candidates for surgery.

Viscosupplementation, despite being beneficial, has its limits. The procedure does not halt the degenerative process of OA or regenerate the damaged cartilage. This rather acts as a symptomatic treatment modality, which can be an add-on along with other therapies, which include physical therapy, lifestyle changes, and medications. This can also hold implications for patient-to-patient variability in effect and the requirement for a treatment series with all the attendant limitation this implies for the patient and health care provider.

A growing awareness of osteoarthritis and demand for effective, minimally invasive treatment are resulting in the growth of the viscosupplementation market. As further improvement is shown in the preparation of HA and the techniques of delivery, its safety and efficacy would further improve, making it an expanding use in clinical practice. Further, studies on the alternative viscosupplementation agents in their pros and cons are under study, likely to shape the outlook of the market in near future. Because of increasing age and prevalence of osteoarthritis, the use of viscosupplementation will grow to be vital in the maintenance of joint health and quality of life among patients.

Market Drivers

Increasing Prevalence of Osteoarthritis Among Geriatric Population

• The increasing burden of osteoarthritis cases in the geriatric population is viewed as a grave concern to public health and healthcare management. Osteoarthritis, a degeneration of a joint with erosion of cartilage and underlying bone, rather occurs quite predominantly in older adults because of the normal process of aging and secondary cumulative effects of wear and tear that naturally occur across joints over many years. As the population of the world continues to age, so too does the number of patients suffering from osteoarthritis, brought about by increased life expectancy and the growing numbers of older people. This pose brings about an increased frequency of osteoarthritis through symptoms such as joint pain, stiffness, and reduced mobility. These significantly reduce the quality of life of those affected. It also means that increasing vulnerability to osteoarthritis among the aging population puts additional pressure on healthcare systems, further calling for better management strategies and interventions in the face of an increased burden of demand for treatment and support. This has, therefore, placed an increased burden from osteoarthritis cases among the elderly on innovative therapies like viscosupplementation for alleviating symptoms and improving the wellbeing outlook in this vulnerable population group.

Increasing Number of Sports Injuries

• The rising number of sports injuries has become a matter of serious concern while more and more people in all age groups are engaging themselves in physical activities and competitive sports. Some reasons for this increase may include the rising intensity of athletic training, growing participation in professional and amateur sports, and increasing emphasis on performance and competition. Thus, athletes—professional and recreational alike—have more of a chance to suffer from sprains, strains, fractures, and joint damage due to the amount of wear and tear which the body takes in from such activities. Another fact is that the advancement in sports medicine and diagnostics itself accounted for better reporting and recognition of injuries, further underlining the problem. This trend underlines that sports-related injuries need to be associated with effective preventive measures, prompt treatment, and rehabilitation strategies in order to deal with and mitigate them. One such reason for growing awareness regarding sports injuries is the increasing demand for newer therapies and technologies, such as viscosupplementation, for the recovery and maintenance of joint health among active individuals.

Market Trends

Advancements in Hyaluronic Acid Formulations

• The progress made in the HA formulations has significantly improved the efficiency and duration of viscosupplementation therapy in joint disorders. The latest developments are directed at increases in the molecular properties so that HA can provide a more durable and potent relief of the symptoms of osteoarthritis. The innovations include cross-linked hyaluronic acid, where chemical modifications have been used to make a more stable, more viscous gel that stays in the joint cavity much longer in order to give prolonged pain relief and joint lubrication. In addition, ongoing research is directed toward the development of higher molecular weight HA formulations: naturally mimicking the properties of synovial fluid, these formulations would provide better cushioning and shock-absorbing capabilities. It not only provides greater efficacy for viscosupplementation in general but also results in a lower number of injections, which is also convenient for the patient and ensures satisfaction. This ever-changing HA technology opens avenues for much more specific and effective treatment technologies in view of the various sufferers of joint pain and degeneration.

Market Restraining Factors

Side Effects Associated with Hyaluronic Acid Cycles

• HA injections for viscosupplementation are not completely free of some possible side effects, mostly of a mild and transitory nature. Common side effects include local injection site reactions such as swelling, redness, or tenderness; these typically disappear in several days. Some patients may experience joint pain or stiffness shortly after the injection, which might represent a transient exacerbation of their symptoms. In very few instances, however, infection or allergic reactions can be serious, even though extremely rare. Others may experience an increase in their pain or flare-up of symptoms shortly after the injection that normally subsides with time. More specifically, the side effects—most of which are generally mild and self-limiting—point to a need for proper patient assessment and monitoring on the part of healthcare providers in relation to the safe and effective use of HA treatments.

Key Industry Developments

In November 2022, Anika Therapeutics, Inc., a prominent company in joint preservation, has achieved the primary objective in the Phase III study for its drug, Cingal. This medication aims to offer extended pain relief for individuals suffering from knee osteoarthritis (OA). Securing FDA approval and launching Cingal in the United States are key goals for the company. Successful clinical trials like this enhance an organization’s research and development capabilities, providing a significant competitive edge in the market.

Report Coverage

The report will cover the qualitative and quantitative data on the global Viscosupplementation Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations:

Viscosupplementation Market Players Analysis:

• DePuy Synthes
• Fidia Farmaceutici S.p.A
• Sanofi
• Smith & Nephew PLC
• Anika Therapeutics, Inc.
• Seikagaku Corp.
• Zimmer Biomet
• Ferring Pharmaceuticals B.V.
• Lifecore Biomedical
• LG Life Sciences Ltd.
• Hoffmann-La Roche Ltd.

Viscosupplementation Market Segmentation

By Product

• Single Injection
• Three Injection
• Five Injection

By End-use

• Hospitals
• Orthopedic Clinics/ASCs

Segmentation Analysis

The market scope is segmented because of by Product, by End-use.

By Product

Based on the Product of the market is segmented into Single Injection, Three Injection, Five Injection.

The three-injection segment has always been the leading product segment in the viscosupplementation market. It can be attributed to the balance it strikes between its effectiveness and patient compliance, which are definitely more cost-effective. Providing a realistic middle course to single and five injections, the three-injection course stretches the period of relief adequately to about six months, which tallies well with the usual intervals for treatment courses that are required to manage osteoarthritic symptoms. This has greatly elevated its favour as it can really provide the promise of effective pain alleviation and improvement in joint function without excessively frequent or long treatment schedules.

Certainly, products requiring a single injection are more convenient and less costly up front, but they generally provide shorter-term relief and require more frequent re-treatment, all of which impacts the overall compliance by patients and long-term cost-efficacy. On the other end, five-injection regimens have extended relief and fewer injections overall but are generally more expensive and less appealing to patients who are hesitant about the duration and frequency of treatment.

By End-use

Based on the End-use of the market is segmented into Hospitals, Orthopaedic Clinics/ASCs.

Orthopaedic clinics and ASCs have turned out to be the dominant end-use segments in the viscosupplementation market. Now, why is that? First of all, orthopaedic clinics and ASCs are concerned with the treatment of musculoskeletal disorders such as osteoarthritis, the very reason for which viscosupplementation procedures are performed. The infusion facilities are endowed with the necessary experience and infrastructure to deliver focused and potent treatments that attract a high number of patients seeking relief from various joint aches and mobility complications.

These orthopaedic clinics and ASCs will, in turn, host a wide array of specialty services targeting the problems of the patient at large. These shall include advanced diagnostic tools and minimally invasive procedures. This means that there will be a more concentrated, efficient focus on viscosupplementation, thus ultimately yielding improved patient outcomes and increased patient satisfaction. Moreover, the trend toward outpatient care and increasing preference for minimally invasive procedures have further enhanced the role of ASCs in the viscosupplementation market. Generally, ASCs offer less recovery time and are associated with lower costs compared to a hospital setting—hence, more attractive to both patients and payers.

Regional Snapshots

It provides the analysis of markets in North America, Europe, Asia-Pacific, Latin America, and MEA by region. North America has historically held the largest share of the viscosupplementation market and is anticipated to continue doing so during the forecast period, owing to several influencing factors. First, this region dominates the market due to the developed healthcare infrastructure in this region, then it is followed by the presence of a huge aging population affected by osteoarthritis, and finally, it is further supported by substantial investment in medical research and development. North America, in particular the United States, offers a much-established market for viscosupplementation treatment procedures, as it is well-endowed with advanced treatment facilities and presents a high level of patient awareness. Moreover, some leading pharmaceuticals and medical devices companies are operating within this region as well, thereby strengthening its lead on the global market through innovation, continuity, and a constant supply of new innovative products.

The fastest-growing viscosupplementation market, however, is expected to be that of the Asia-Pacific region in the near future. Factors driving such growth include the increasing population, rising prevalence of osteoarthritis, and increased spending on healthcare in the region. With a growing middle class and enhanced disposable incomes, there exists an increased demand for better healthcare services and treatment procedures. Furthermore, betterment in healthcare infrastructure and access to medical technologies in countries like China, India, and Japan are providing a conducive environment for the adoption of viscosupplementation therapies in such countries. Increasing awareness and acceptance of advanced treatments among such emerging economies further accelerate their growth. Hence, the Asia-Pacific region is projected to show considerable market growth due to these highly dynamic and changing variables.

Viscosupplementation Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report:

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Viscosupplementation Market valued?
• Which region has the largest share in 2024 for the global Viscosupplementation Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Viscosupplementation Market

• Historic year: 2019- 2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Viscosupplementation Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends